Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis | Zendy

Maarten A. de Jong | Zendy; Katarina Mirković | Zendy; Rik Mencke | Zendy; Joost G.J. Hoenderop | Zendy; René J.M. Bindels | Zendy; Marc G. Vervloet | Zendy; JanLuuk Hillebrands | Zendy; Jacob van den Born | Zendy; Gerjan Navis | Zendy; Martin H. de Borst | Zendy

Open Access

Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis

Author(s) -

Maarten A. de Jong,

Katarina Mirković,

Rik Mencke,

Joost G.J. Hoenderop,

René J.M. Bindels,

Marc G. Vervloet,

JanLuuk Hillebrands,

Jacob van den Born,

Gerjan Navis,

Martin H. de Borst

Publication year - 2016

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfw105

Subject(s) - medicine , losartan , fibrosis , endocrinology , kidney , renin–angiotensin system , angiotensin ii receptor type 1 , mineralocorticoid receptor , kidney disease , angiotensin ii , blockade , pharmacology , receptor , blood pressure

Blockade of the renin-angiotensin-aldosterone system (RAAS) retards progression of chronic kidney disease. Yet, in many patients, the renoprotective effect is incomplete. A high circulating level of the phosphaturic hormone fibroblast growth factor 23 is associated with an impaired response to RAAS blockade-based therapy in clinical studies. Therefore, we addressed whether administration of recombinant fibroblast growth factor 23 (FGF23) interferes with the efficacy of angiotensin receptor blocker (ARB) treatment in a mouse model of renal fibrosis [unilateral ureteral obstruction (UUO)].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research